Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib as a first-line treatment for patients with metastatic renal cell carcinoma.
Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.
Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.
The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.